Electrolyte type and nozzle composition affect the process of vibrating-membrane nebulization

Beck-Broichsitter, Moritz; Oesterheld, Nina

doi:10.1016/j.ejpb.2017.05.004

Cited by 13 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evaluation of the droplet size in the aerosol generated with the Aeroneb nebulizer resulted in MSDS of 4.52±1.59 µm, confirming that most of the droplets were within the respirable range. These results are well aligned with previously reported values using the same system (Ghazanfari et al 2007;Zhang et al 2007;Beck-Broichsitter et al 2012;Beck-Broichsitter et al 2017).…”

Section: Aerosol Droplet Size Measurementssupporting

confidence: 93%

“…The droplet size obtained after nebulization depends on the electrolyte concentration of the solution, as recently reported (Beck-Broichsitter et al 2017). For this reason, in the current work the aerosol droplet size was determined with a proper dilution of the [ 18 F]FDG solution with purified water, in order to obtain representative results for in vivo experiments.…”

Section: Aerosol Droplet Size Measurementsmentioning

confidence: 81%

See 1 more Smart Citation

Preclinical evaluation of aerosol administration systems using Positron Emission Tomography

Cossío¹,

Gómez‐Vallejo²,

Flores³

et al. 2018

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Pulmonary administration of drugs has recently gained attention because it exhibits numerous advantages compared to oral or intravenous administration. The administration of aerosols for inhalation to animals, however, remains a critical challenge and only a few methods of administration have been developed. Herein, we compare the regional distribution of aerosols in the lungs of wild type rats after pulmonary administration using three different methods: (a) The Penn-Century MicroSprayer® Aerosolizer; (b) an in-house designed aerosol generation system; and (c) the Aeroneb® Lab Micropump Nebulizer. Both the regional distribution and the fraction of aerosol deposited in the lungs were determined by means of radiolabelling of the aerosol followed by in vivo and ex vivo Positron Emission Tomography (PET) imaging and dissection and gamma counting. Endotracheal insufflation using the PennCentury MicroSprayer resulted in >85% of the administered dose accumulated in the lungs, with a non-uniform distribution of the radioactivity in different lobes and a low animal-to-animal reproducibility. Administration using the in-house designed and the Aeroneb nebulizers resulted in a uniform distribution over the lungs, but only a small fraction of the nebulized activity (ca. 0.1%) was deposited in the lungs.

show abstract

Section: Aerosol Droplet Size Measurementssupporting

confidence: 93%

Section: Aerosol Droplet Size Measurementsmentioning

confidence: 81%

Preclinical evaluation of aerosol administration systems using Positron Emission Tomography

Cossío¹,

Gómez‐Vallejo²,

Flores³

et al. 2018

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

show abstract

“…From the findings described, the air-jet nebuliser would appear preferable to that based on vibrating-mesh technology for this specific liposome formulation. The lower efficiency of the vibrating-mesh nebuliser in comparison with air-jet nebuliser for delivering this formulation may be due to the lower energy input for atomisation, lack of an ionic component (particularly a halide) or a surfactant in the formulation and the generation of heat possibly resulting in the liposome aggregation/degradation during 10 min nebulisation as previously reported for thermolabile proteins (Beck-Broichsitter and Oesterheld, 2017;Hertel et al, 2014). Furthermore, the mesh pore could possibly be blocked due to drug crystallisation or inappropriate properties of formulation during nebulisation, resulting in higher resistance when the diameter of mesh apertures was decreased (Chan et al, 2011;Manunta et al, 2011).…”

Section: Measured Aerosol Properties For Air-jet and Vibrating-mesh Nmentioning

confidence: 67%

Aerosol characterisation of nebulised liposomes co-loaded with erlotinib and genistein using an abbreviated cascade impactor method

Nimmano¹,

Somavarapu²,

Taylor³

2018

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Erlotinib and genistein co-loaded liposomes were prepared by the thin-film hydration method. The effect of probe sonication as a size reduction method on drug incorporation and the properties of aerosols generated using air-jet and vibrating-mesh nebulisers was studied. The use of the Next Generation Impactor (NGI) to characterise inhaler formulations is limited by the need accurately to quantify drug deposited across 8 stages and is labour intensive to use. The Fast Screening Impactor (FSI) comprising two impaction stages was compared with the NGI to evaluate its applicability as a simple screening and labour-saving tool to characterise nebulised systems. For the developed liposomal formulations, an air-jet nebuliser generated a two-fold higher fine particle fraction (FPF) than a vibrating-mesh nebuliser. The findings demonstrated that the cooled FSI (5°C) operated at 15 L/min was effective in differentiating the aerosol properties of the nebulised liposome formulations investigated. Overall, the optimised co-loaded liposomes were more effectively delivered by an air-jet nebuliser, than from a vibrating-mesh nebuliser over a 10 min period as determined using the abbreviated impactor.

show abstract

“…The performance of a vibrating-mesh nebulizer can be affected by numerous factors, including viscosity and electrolyte conductivity of the solution, and clogging of the mesh plate by drug crystallization [ 9 , 10 , 11 ]. Beck-Broichsitter et al, evaluated vibrating-mesh nebulizer performance using solutions of different viscosities and reported that particle size measured in volume median diameter decreased as the solution viscosity and nebulizer output rate increased [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Evaluation of a Vibrating-Mesh Nebulizer Repeatedly Use over 28 Days

Lin

Chen

Fink³

et al. 2020

Pharmaceutics

View full text Add to dashboard Cite

This in vitro study evaluates the performance of a disposable vibrating-mesh nebulizer when used for 28 days. A lung model was used to simulate the breathing pattern of an adult with chronic obstructive pulmonary disease. The vibrating-mesh nebulizer was used for three treatments/day over 28 days without cleaning after each test. Results showed that the inhaled drug dose was similar during four weeks of use (p = 0.157), with 16.73 ± 4.46% at baseline and 15.29 ± 2.45%, 16.21 ± 2.21%, 17.56 ± 1.98%, and 17.13 ± 1.81%, after the first, second, third, and fourth weeks, respectively. The particle size distribution, residual drug volume, and nebulization time remained similar across four weeks of use (p = 0.110, p = 0.763, and p = 0.573, respectively). Mesh was inspected using optical microscopy and showed that approximately 50% of mesh pores were obscured after 84 runs, and light penetration through the aperture plate was significantly reduced after the 21st use (p < 0.001) with no correlation to nebulizer performance. We conclude that the vibrating-mesh nebulizer delivered doses of salbutamol solution effectively over four weeks without cleaning after each use even though the patency and clarity of the aperture plate were reduced by the first week of use.

show abstract

Electrolyte type and nozzle composition affect the process of vibrating-membrane nebulization

Cited by 13 publications

References 17 publications

Preclinical evaluation of aerosol administration systems using Positron Emission Tomography

Preclinical evaluation of aerosol administration systems using Positron Emission Tomography

Aerosol characterisation of nebulised liposomes co-loaded with erlotinib and genistein using an abbreviated cascade impactor method

In Vitro Evaluation of a Vibrating-Mesh Nebulizer Repeatedly Use over 28 Days

Contact Info

Product

Resources

About